Yes, Acyclovir-Resistant Strains Respond to Alternatives
Acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV) strains, often seen in immunocompromised patients, can be treated with other antivirals targeting different viral enzymes or mechanisms. Resistance typically arises from mutations in viral thymidine kinase (TK) or DNA polymerase, reducing acyclovir's phosphorylation or incorporation.[1]
What Alternatives Work Best for HSV Resistance?
Foscarnet is the primary option for acyclovir-resistant HSV. It directly inhibits viral DNA polymerase without needing TK activation, effective against TK-deficient mutants. Intravenous dosing (e.g., 40-60 mg/kg every 8 hours) achieves response rates over 80% in clinical studies, though nephrotoxicity requires monitoring.[2][3]
Cidofovir serves as a second-line choice, also bypassing TK via intracellular diphosphate conversion. It's used at 5 mg/kg weekly initially, with similar efficacy but higher renal risk; probenecid co-administration mitigates this.[1][4]
How Does This Apply to VZV Resistance?
For acyclovir-resistant VZV (e.g., in shingles), foscarnet remains first-line, with brivudine as an oral alternative in some regions (not FDA-approved in the US). Imiquimod cream offers topical relief for cutaneous lesions but doesn't eradicate systemic virus.[5]
Why Not Just Use Valacyclovir or Famciclovir?
These prodrugs convert to acyclovir or penciclovir, respectively, so cross-resistance is common in TK-mutant strains. They fail where acyclovir does, limiting their role.[1][2]
Emerging Options and Combinations
Investigational helicase-primase inhibitors like pritelivir show promise against resistant HSV, inhibiting replication upstream of polymerase. Phase 2 trials report viral load reductions in acyclovir failures, but it's not yet approved.[6]
Combining foscarnet with antivirals like letermovir (cytomegalovirus-focused but with HSV activity) is explored in refractory cases.[3]
Key Risks and Patient Considerations
Foscarnet and cidofovir carry renal toxicity (up to 30% incidence), electrolyte imbalances, and IV administration needs, restricting use to severe cases. Resistance testing via genotypic assays guides therapy; phenotypic testing confirms susceptibility.[4]
Consultation with infectious disease specialists is standard for immunocompromised patients, where mortality from resistant HSV encephalitis can exceed 50% without prompt switching.[2]
Sources
[1] UpToDate: Treatment of acyclovir-resistant HSV
[2] Clin Infect Dis: Management of acyclovir-resistant HSV/VZV
[3] CID: Antiviral therapy for resistant herpesviruses
[4] IDSA Guidelines: HSV infections
[5] CDC: VZV resistance management
[6] ClinicalTrials.gov: Pritelivir for acyclovir-resistant HSV